Cardiologists may gain benefits with SGLT2 inhibitors in patients with heart failure with preserved ejection fraction (HFpEF), according to research released at ESC Congress 2021. The EMPEROR-Preserved trial reviewed cardiovascular outcomes in 5988 heart failure patients with >40% ejection fraction who were on empagliflozin or placebo over median 26.2 months. Empagliflozin patients were significantly less ...
SGLT2 inhibitor results a ‘huge win’ for HFpEF patients
By Natasha Doyle
31 Aug 2021